logo
India saw over 32 million disaster displacements in a decade: IDMC report

India saw over 32 million disaster displacements in a decade: IDMC report

Natural disasters such as floods and storms displaced 32.3 million people in India between 2015 and 2024, according to a report by the Geneva-based Internal Displacement Monitoring Centre (IDMC). India ranks third globally after China and the Philippines in terms of internal displacements caused by natural hazards.
The report highlights that disasters triggered 264.8 million internal displacements across 210 countries and territories over the past decade, with East and South Asian countries among the worst affected. China recorded 46.9 million displacements, followed closely by the Philippines with 46.1 million.
'At the country level, Bangladesh, China, India, the Philippines and the US recorded the highest figures over the past decade,' the report stated.
Floods and storms behind 90% of global disaster displacement
According to IDMC, 90 per cent of global disaster-related displacements between 2015 and 2024 were caused by floods and storms. Storms alone triggered 120.9 million displacements during this period, while floods were responsible for 114.8 million.
Cyclones, including Cyclone Amphan in 2020, accounted for 92 per cent of all storm-related displacements worldwide.
The report noted a rising trend in disaster-induced displacement, driven by more frequent and intense hazards, improved data collection at the national level, and enhanced global monitoring capacities.
India recorded 5.4 million displacements in 2024 alone
In 2024, a record 45.8 million internal displacements were reported globally—well above the decadal average of 26.5 million. India accounted for 5.4 million of these, marking the highest annual figure recorded in the country over the past 12 years.
Many of these movements were preemptive evacuations, according to the report, reflecting the efforts of governments and local communities in disaster-prone areas to save lives and minimise injury. However, millions remain displaced for months or years after major floods, storms and other hazards.
Vulnerable populations hit hardest
The IDMC emphasised that disaster displacement disproportionately affects the most vulnerable populations.
'They are often forced to flee repeatedly and for longer periods of time, which heightens their pre-existing vulnerabilities and reinforces social inequalities,' the report stated.
Climate conditions could displace 32 million annually
The IDMC warned that, under current climate conditions, an annual average of 32 million people globally are likely to be displaced due to hazards such as riverine and coastal flooding, drought and cyclonic winds.
That figure could double if global temperatures rise more than 1.5°C above pre-industrial levels (1850–1890), the report cautioned.
'Left unaddressed, disaster displacement will be a major obstacle to the achievement of global goals, such as those set by the Sendai Framework for Disaster Risk Reduction, the Paris Agreement and the 2030 Agenda for Sustainable Development,' it concluded.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO

Economic Times

timean hour ago

  • Economic Times

Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO

Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version of semaglutide across 87 countries by 2026, alongside developing 26 GLP-1 products over the next decade. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET.'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.'The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver.'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query.'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade.'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio company's India and emerging markets business grew 11% and 17% company's EBITDA margin for the first quarter stood at 26.7%.

Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO

Time of India

timean hour ago

  • Time of India

Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO

A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET. 'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.' Explore courses from Top Institutes in Please select course: Select a Course Category Technology Leadership Project Management Healthcare Management Data Analytics Data Science others Cybersecurity Artificial Intelligence Design Thinking Degree Product Management Public Policy Data Science MCA Finance MBA Others healthcare Operations Management PGDM CXO Digital Marketing Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo 'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query. 'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he said. Live Events The company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade. 'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Israeli. On Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% y-o-y. Israeli said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product launches. The company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% year-on-year. However, revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio acquisition. The company's India and emerging markets business grew 11% and 17% respectively. The company's EBITDA margin for the first quarter stood at 26.7%.

Chhattisgarh's Tiriya gram sabha recognised globally for community-led forest governance
Chhattisgarh's Tiriya gram sabha recognised globally for community-led forest governance

New Indian Express

time3 hours ago

  • New Indian Express

Chhattisgarh's Tiriya gram sabha recognised globally for community-led forest governance

RAIPUR: Tucked deep inside south Chhattisgarh's Bastar division, Tiriya village has been recognised among the top 15 mentions, out of the 190+ nominated communities, for the 2025 Collective Action Awards by the Rights and Resources Initiative (RRI). Tiriya's model stands as a resilient example on how tribal (Adivasi) communities can lead inclusive, sustainable development rooted in traditional knowledge and collective action in Bastar region. The RRI is a global coalition of grassroots organisations aimed at improving coordination and support for the recognition of land rights for indigenous people across Africa, Asia and Latin America. The global efforts intended to safeguard nature and preserve traditional knowledge for future generations are much appreciated. The achievement of Tiriya has been supported by the Bastar-based team of ATREE, which has facilitated key steps in the community forest rights (CFR) claim-making and community planning processes. The global recognition celebrates Tiriya's exemplary grassroots efforts in securing community forest rights, strengthening collective governance and pioneering a self-sustaining eco-tourism model.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store